C147 - Multiple Sclerosis Therapy: Disease-modifying Treatment II

Event Time: Wednesday April 25, 2018 1:00 pm to 3:00 pm
Topic(s): MS and CNS Inflammatory Disease, Foundations in Clinical Neurology for APPs
Director(s): John Rose MD, FAAN
Description: The DMT II  course is designed to complement the information on immunotherapy in the DMT I course. The speakers will address treatment of two major populations of MS patients for which immunotherapy is only now emerging; Pediatric MS patients and the Progressive MS patients.  There has been a general consensus that the DMTs approved for adults are beneficial in children.  Clinical trials in Pediatric MS have recently concluded or are reaching conclusion soon and results will be submitted for FDA approval.  The treatment of progressive forms of MS has advanced including approved therapy for Primary Progressive MS.  An advanced trial for treatment of Secondary Progressive MS has been successfully completed and may lead to an approved therapy in the near future.  In the course we will the evolution of immunotherapy.  Finally, we will also present the current status of new therapies to promote remyelination. 
Completion Message: Participants should be able to: 1) Know the effects of immunotherapy on Pediatric MS and prospects for formally approved therapy 2) Discuss the status of immunotherapy for Progressive Forms of MS 3) Know the new directions in immunotherapy for MS 4) Evaluate the status of emerging treatments for demyelination
CME Credits: 2
Core Competencies: Medical Knowledge, Patient Care

Ready to register for the 2019 AAN Annual Meeting?

Register Now

Related Courses